- Price
- $1.11
- Day
- +3.74%
- Mkt Cap
- $118.91M
- 52W Range
- $0.64 – $2.19
- Volume
- 319.8K
- Beta
- 1.49
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
ROCKVILLE, Md., July 21, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs.
Read full article
ROCKVILLE, Md., July 15, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the second quarter 2026 after the U.S. market close on Wednesday, August 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
Read full article